Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that has completed Phase II clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and FIN-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and crohn's disease. The company has collaboration and license agreements with Millennium Pharmaceuticals, Inc.; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.
IPO Year: 2021
Exchange: NASDAQ
Website: finchtherapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/9/2022 | $17.00 | Buy | H.C. Wainwright |
15-12G - Finch Therapeutics Group, Inc. (0001733257) (Filer)
EFFECT - Finch Therapeutics Group, Inc. (0001733257) (Filer)
S-8 POS - Finch Therapeutics Group, Inc. (0001733257) (Filer)
POS AM - Finch Therapeutics Group, Inc. (0001733257) (Filer)
S-8 POS - Finch Therapeutics Group, Inc. (0001733257) (Filer)
S-8 POS - Finch Therapeutics Group, Inc. (0001733257) (Filer)
25 - Finch Therapeutics Group, Inc. (0001733257) (Filer)
8-K - Finch Therapeutics Group, Inc. (0001733257) (Filer)
10-Q - Finch Therapeutics Group, Inc. (0001733257) (Filer)
8-K - Finch Therapeutics Group, Inc. (0001733257) (Filer)
H.C. Wainwright initiated coverage of Finch Therapeutics with a rating of Buy and set a new price target of $17.00
Jefferies initiated coverage of Finch Therapeutics with a rating of Buy and set a new price target of $29.00
Evercore ISI initiated coverage of Finch Therapeutics with a rating of Outperform and set a new price target of $34.00
BofA Securities initiated coverage of Finch Therapeutics with a rating of Buy and set a new price target of $25.00
4 - Finch Therapeutics Group, Inc. (0001733257) (Issuer)
4 - Finch Therapeutics Group, Inc. (0001733257) (Issuer)
4 - Finch Therapeutics Group, Inc. (0001733257) (Issuer)
4 - Finch Therapeutics Group, Inc. (0001733257) (Issuer)
4/A - Finch Therapeutics Group, Inc. (0001733257) (Issuer)
4 - Finch Therapeutics Group, Inc. (0001733257) (Issuer)
4 - Finch Therapeutics Group, Inc. (0001733257) (Issuer)
4 - Finch Therapeutics Group, Inc. (0001733257) (Issuer)
4 - Finch Therapeutics Group, Inc. (0001733257) (Issuer)
4 - Finch Therapeutics Group, Inc. (0001733257) (Issuer)
BOSTON, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (NASDAQ:FNCH) ("Finch" or the "Company"), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today announced that it has provided notification to The Nasdaq Stock Market, LLC ("Nasdaq") of its intent to delist the Company's common stock, par value $0.001 per share (the "Common Stock"), from the Nasdaq Global Select Market. Finch expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the "SEC") and Nasdaq relating to the delisting of its Common Stock on or about October 31, 2024. The removal of the Common Stock from Nas
BOSTON, June 09, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch", "Finch Therapeutics" or the "Company") (NASDAQ:FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today announced it will effect a one-for-30 reverse stock split of its issued and outstanding common stock. Finch stockholders approved an amendment to its Amended and Restated Certificate of Incorporation to effect the reverse stock split at Finch's Annual Meeting of Stockholders held on June 8, 2023. The reverse stock split is intended to increase the per share trading price of Finch's common stock to enable Finch to satisfy the minimum price requirement for
SOMERVILLE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch", "Finch Therapeutics" or the "Company") (NASDAQ:FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today reported first quarter 2023 financial results and provided business updates. "Finch has continued to execute on its strategy to advance its novel microbiome technology through partnerships and collaborations, highlighted by the recent investigator-sponsored clinical trial agreement with Brigham and Women's Hospital to evaluate CP101 for the treatment of ulcerative colitis and an amended license agreement with the University of Minnesota," said
Matthew P. Blischak, an experienced life sciences executive and intellectual property counsel, appointed as Chief Executive Officer effective May 16, 2023; Mark Smith, PhD, to complete his time as CEO effective May 15 Lance Thibault, Managing Director of Danforth Advisors, to serve as Chief Financial Officer effective May 16, 2023; Marc Blaustein to complete his time as Chief Operating Officer and principal financial officer effective May 15 SOMERVILLE, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch", "Finch Therapeutics" or the "Company") (NASDAQ:FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, toda
SOMERVILLE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch", "Finch Therapeutics" or the "Company") (NASDAQ:FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today announced that it has entered into a clinical trial agreement with Brigham and Women's Hospital for the evaluation of CP101, a Complete Consortia microbiome therapeutic, in ulcerative colitis. The Company also announced updates to its license agreement with the University of Minnesota. Under the clinical trial agreement, Brigham and Women's Hospital will conduct an investigator-sponsored trial that is designed to compare two doses of CP101 i
SOMERVILLE, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch", "Finch Therapeutics" or the "Company") (NASDAQ:FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today reported fourth quarter and full year 2022 financial results and provided business updates. "We believe that Finch has made significant progress towards restructuring the business to maximize value for shareholders through our robust intellectual property estate, including by continuing to support the advancement of our microbiome technology through partnerships and collaborations," said Mark Smith, PhD, Chief Executive Officer of Finch Ther
SOMERVILLE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (the "Company," "Finch," or "Finch Therapeutics") (NASDAQ:FNCH) today announced its decision to discontinue the PRISM4 Phase 3 trial of CP101 in recurrent C. difficile infection (CDI) and focus on realizing the value of its intellectual property estate and other assets. This decision follows an assessment by Finch's management team and board of directors of several factors, including the Company's outlook for securing additional capital or partnerships to help fund the CP101 program through important milestones, slower than anticipated enrollment in the PRISM4 trial, the harmful impact of ongoing unauthoriz
Patient dosing underway in PRISM4 Phase 3 trial of CP101 in recurrent CDITopline PRISM4 data anticipated in H1 2024 Anticipated cash runway into Q2 2024 SOMERVILLE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today provided corporate updates and reported financial results for the third quarter ended September 30, 2022. "We are pleased with the tremendous progress our team has made recently to advance the development of our lead program, with patient dos
SOMERVILLE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced that the company will present at the following investor conferences: Jefferies London Healthcare ConferenceWednesday, November 16, 2022 at 10:55 am GMTCorporate presentation by Howard Franklin, MD, MBA, Chief Medical Officer Evercore ISI HealthCONx ConferenceThursday, December 1, 2022 at 11:20 am ETFireside chat with Mark Smith, PhD, Chief Executive Officer Live webcasts of both ev
SOMERVILLE, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced the presentation of biomarker data from PRISM-EXT, a Phase 2 open-label trial of CP101 in recurrent C. difficile infection (CDI), at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting, being held October 21-26, 2022 in Charlotte, NC. Finch also announced today that the company has proceeded with patient dosing in PRISM4, a Phase 3 trial of CP101 for the prev
SC 13G - Finch Therapeutics Group, Inc. (0001733257) (Subject)
SC 13G - Finch Therapeutics Group, Inc. (0001733257) (Subject)
SC 13G - Finch Therapeutics Group, Inc. (0001733257) (Subject)
SC 13D - Finch Therapeutics Group, Inc. (0001733257) (Subject)
SC 13D - Finch Therapeutics Group, Inc. (0001733257) (Subject)
SC 13G - Finch Therapeutics Group, Inc. (0001733257) (Subject)
FDA lifted clinical hold on IND for CP101Enrollment in PRISM4 Phase 3 trial of CP101 in recurrent CDI expected to proceed in H2 2022$15 million drawn from new $55 million term debt facility Anticipated cash runway into Q2 2024Corporate update call today at 8am ET SOMERVILLE, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today provided a corporate update and reported financial results for the first quarter ended March 31, 2022. "Finch made several important
SOMERVILLE, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced it will host a conference call and live webcast on Monday, May 16, 2022 at 8:00am ET to discuss updates to its development programs and other business highlights. The conference call can be accessed by dialing (833) 649-1186 (domestic) or (270) 823-1080 (international) and entering conference ID 8451806. The live webcast can be accessed by visiting the ‘Investors & News' section of
SOMERVILLE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch", "Finch Therapeutics" or the "Company") (NASDAQ:FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today reported first quarter 2023 financial results and provided business updates. "Finch has continued to execute on its strategy to advance its novel microbiome technology through partnerships and collaborations, highlighted by the recent investigator-sponsored clinical trial agreement with Brigham and Women's Hospital to evaluate CP101 for the treatment of ulcerative colitis and an amended license agreement with the University of Minnesota," said
Matthew P. Blischak, an experienced life sciences executive and intellectual property counsel, appointed as Chief Executive Officer effective May 16, 2023; Mark Smith, PhD, to complete his time as CEO effective May 15 Lance Thibault, Managing Director of Danforth Advisors, to serve as Chief Financial Officer effective May 16, 2023; Marc Blaustein to complete his time as Chief Operating Officer and principal financial officer effective May 15 SOMERVILLE, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch", "Finch Therapeutics" or the "Company") (NASDAQ:FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, toda
SOMERVILLE, Mass., March 31, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today reported fourth quarter and full year 2021 financial results and provided business updates. "Finch achieved many significant milestones in 2021, including new clinical data readouts that support our lead product candidate, CP101, for the prevention of recurrent C. difficile infection and the advancement of our TAK-524 ulcerative colitis development program to Takeda for further development. F
Bryan Gillis, MBA, appointed Chief Technology OfficerAlka Batycky, PhD, appointed Chief Development OfficerHoward Franklin, MD, MBA, appointed Senior Vice President, Late-Stage Development and GI Therapeutic Area Lead SOMERVILLE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced the appointment of Bryan Gillis, MBA, to Chief Technology Officer, Alka Batycky, PhD, to Chief Development Officer, and Howard Franklin, MD, MBA, to Senior Vice Preside
SOMERVILLE, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced that Samuel Allen (Al) Hamood has joined Finch's Board of Directors. Mr. Hamood is an accomplished executive with over 30 years of experience in finance, business development, corporate strategy, and M&A across several global industry sectors. "Through the course of his career, Al has been instrumental in developing and driving growth strategies and translating those strategies into
SOMERVILLE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced the appointment of Marc Blaustein as Chief Operating Officer. Mr. Blaustein is a seasoned biopharmaceutical executive with more than 20 years of experience building and leading companies and critical business functions including operations, business development, program management, and manufacturing. "I am delighted to welcome Marc to the Finch team at a time when we are positioned
Takeda to accelerate leadership role in advancing FIN-524/TAK-524 ulcerative colitis development programTopline safety and efficacy data from more than 130 recurrent CDI patients treated with CP101 in open label PRISM-EXT trial expected in H2 2021Continued progress advancing development programs, with clinical data across multiple programs anticipated in 2022 SOMERVILLE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today reported financial results for
SOMERVILLE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (NASDAQ:FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs, today announced that Susan E. Graf has joined Finch's Board of Directors and will serve as Chair of the Audit Committee. Ms. Graf is an accomplished biopharma executive with more than 25 years of experience spanning corporate strategy, finance, business development, M&A, and the development and commercialization of biopharmaceuticals. "With Finch's recent IPO, strong Phase 2 data from their lead can